Titan Falls Short With Initial Phase IIb Results

Titan Pharmaceuticals failed to meet its primary and secondary endpoints in its Phase IIb trial testing Spheramine for moderate-to-advanced Parkinson’s disease.

Conducted by partner Bayer Schering Pharma, the multicenter, double-blind, randomized study of 71 patients evaluated the safety, tolerability and efficacy of the drug.

Patients were randomized to receive either injections of the drug inside the brain or a sham surgery in which a burr hole was drilled without brain penetration or drug injection. No significant difference was shown between the treatment groups, Titan said.